Optimal Surface Pre-Reacted Glass Filler Ratio in a Dental Varnish Effective for Inhibition of Biofilm-Induced Root Dentin Demineralization.

A unique type of dental varnish (DV) containing surface pre-reacted glass (S-PRG) fillers of different concentrations was evaluated to determine the unpresented optimal ratio for inhibiting root dentin bio-demineralization. S-PRG DVs (10% to 40%)­10%-S, 20%-S, 30%-S, and 40%-S­were applied to bovine root dentin blocks and compared with controls­0%-f (no S-PRG) and 5%-NaF (5%-NaF). The Streptococcus mutans biofilm challenge was executed inside and outside an oral biofilm reactor for 7 days. The specimens were examined using a confocal laser scanning microscope and swept-source optical coherence tomography. Furthermore, they were observed using a scanning electron microscope and analyzed using energy-dispersive X-ray spectroscopy. The roughness (SzJIS) due to leaching of DV materials and demineralization depth were significantly less in the S-PRG groups than the control groups (p < 0.05). Complete or partially plugged dentinal tubules (DTs) were observed in 20%-S, 30%-S, and 40%-S, while wide-open DTs were observed more in controls. Cylindrical tags were present in groups containing more than 20% S-PRG. F, Na, Al, and Sr were detected in a higher percentile ratio in the 20%-S, 30%-S, and 40%-S groups compared to 0%-f and 10%-S. Nonetheless, it is suggested that incorporating 20% to 30% S-PRG fillers in DVs would be effective enough as an anti-demineralization coating, together with supplementing minerals; further evaluation is required to validate these findings.

Selection of Mycoplasma genitalium strains harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 g dose of azithromycin.

OBJECTIVE: A single 1 g dose regimen of azithromycin has been recommended for the treatment of Mycoplasma genitalium infections. The authors evaluated whether this regimen could select M genitalium strains with macrolide resistance after treatment for M genitalium-positive non-gonococcal urethritis. METHODS: In seven men with non-gonococcal urethritis, who were infected with M genitalium without macrolide resistance-associated mutations but experienced microbiological azithromycin treatment failure, M genitalium DNAs in their post-treatment urine specimens were examined for mutations in the 23S rRNA gene and the ribosomal protein genes of L4 and L22. To assess the relatedness of M genitalium strains before and after treatment, their DNAs in pretreatment and post-treatment urine were genotyped by analysing short tandem repeats of an AGT/AAT unit in the MG309 gene and single nucleotide polymorphisms in the MG191 gene. RESULTS: In four of seven patients, M genitalium in post-treatment urine had an A-to-G transition at nucleotide position 2071 or 2072, corresponding to 2058 or 2059 in the 23S rRNA gene of Escherichia coli. In one of the four strains, Pro81Ser in the ribosomal protein L4 accompanied the mutation in the 23S rRNA gene. The genotyping of M genitalium DNAs suggested that these four post-treatment strains were selected from the respective closely related or identical pretreatment strains without macrolide resistance-associated mutations by the treatment. CONCLUSIONS: The single 1 g dose treatment of azithromycin could select M genitalium strains harbouring macrolide resistance-associated mutations. For M genitalium, this regimen might increase the risk of macrolide resistance selection after treatment.